|Other names||Lonapegsomatropin-tcgd; Lonapegsomatropin Ascendis Pharma; rhGH-PEG; ACP-011; ΤransConPEG hGh; WHO-10598|
|Drug class||Growth hormone receptor agonist|
|Main uses||Growth hormone deficiency|
|Side effects||Headache, joint pain, low thyroid, pain at the site of injection|
|Chemical and physical data|
Lonapegsomatropin, sold under the brand name Skytrofa, is a medication used to treat growth hormone deficiency. It may be used in children from the ages of 1 to 18 year. It is given by injection under the skin once per week.
Common side effects include headache, joint pain, low thyroid, and pain at the site of injection. Other side effects may include allergic reactions, cancer, diabetes, intracranial hypertension, swelling, pancreatitis, and slipped capital femoral epiphysis. It is a human growth hormone (somatropin) that has been developed to be long acting.
Lonapegsomatropin was approved for medical use in the United States in 2021 and Europe in 2022. In the United States it costs 2,800 to 12,300 USD per week, depending on the weight of the child. As of 2022 it is not yet commercial available in Europe.
The typical dose is 0.24 mg/kg by injection once per week.
- "Skytrofa- lonapegsomatropin-tcgd injection, powder, lyophilized, for solution". DailyMed. Archived from the original on 1 October 2021. Retrieved 30 September 2021.
- "Lonapegsomatropin Ascendis Pharma EPAR". European Medicines Agency. 10 November 2021. Archived from the original on 16 March 2022. Retrieved 16 March 2022.
- "Skytrofa: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 26 August 2021. Retrieved 25 August 2021.
- "Skytrofa Prices, Coupons, Copay & Patient Assistance". Drugs.com. Retrieved 27 October 2022.
- "Lonapegsomatropin". SPS - Specialist Pharmacy Service. 7 March 2019. Archived from the original on 17 January 2022. Retrieved 27 October 2022.
- Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, et al. (July 2021). "Weekly Lonapegsomatropin in Treatment-Naïve Children with Growth Hormone Deficiency: The Phase 3 heiGHt Trial". The Journal of Clinical Endocrinology and Metabolism. 106 (11): 3184–3195. doi:10.1210/clinem/dgab529. PMC 8530727. PMID 34272849.